The stock may react positively to the advancement of late-stage assets, particularly CORDStrom™ regulatory filings, but traders should monitor cash burn and upcoming financing risk as the company remains pre-revenue with limited near-term income potential.
Price Chart
Executive Summary
INmune Bio reported a net loss of $45.9 million for 2025, wider than the $42.1 million loss in 2024, driven by a $16.5 million impairment charge and reduced R&D spending. The company highlighted progress in its CORDStrom™ and XPro™ late-stage programs, with regulatory filings expected in 2026 and cash runway extending to Q1 2027. Despite advancing clinical assets, the increased loss and lack of revenue raise concerns about sustainability.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $45.9 million vs. $42.1 million in 2024
- Research and development expenses decreased to $20.7 million from $33.2 million
- Impairment charge of $16.5 million related to in-process R&D in 2025
- Cash and cash equivalents were $24.8 million as of December 31, 2025
- Cash runway expected through Q1 2027
- MAA for CORDStrom™ expected in UK mid-summer 2026, FDA BLA in Q4 2026
- XPro™ advancing to Phase 2b/3 for Alzheimer’s with FDA alignment
- No revenue in 2025, only $50K in total
Financial Impact
Increased net loss of $3.8 million YoY with a $16.5 million non-cash impairment; minimal revenue generation
Risk Factors
- Continued losses and reliance on future financings
- Clinical trial failure risk for CORDStrom™ and XPro™
- Regulatory delays or rejections
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264946 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $1.61 | awaiting T+60 | — | $1.43 (−11.18%) |
Sep 16, 2026 5w ago | 3 | $2.18 | awaiting T+60 | — | $1.43 (−34.40%) |
Jul 9, 2026 15w ago | Press Release | $1.79 $1.93 | ▲ +7.82% | ▲ +6.19% | $1.43 (−20.11%) |
Jul 1, 2026 16w ago | 8-K | $1.68 | awaiting T+60 | — | $1.43 (+14.88%) |
Jun 23, 2026 17w ago | 8-K | $1.35 | awaiting T+60 | — | $1.43 (+5.93%) |
Jun 17, 2026 18w ago | 8-K | $1.45 | awaiting T+60 | — | $1.43 (−1.38%) |
Jun 2, 2026 20w ago | 8-K | $1.32 $2.40 | ▲ +81.82% | ▲ +79.32% | $1.43 (+8.33%) |
May 7, 2026 24w ago | Press Release | $1.43 $1.91 | ▲ +33.57% | ▲ +28.73% | $1.43 (−0.00%) |
May 5, 2026 24w ago | 8-K | $1.52 $1.75 | ▲ +15.13% | ▲ +13.07% | $1.43 (−5.92%) |
Apr 30, 2026 25w ago | Press Release | $1.43 | awaiting T+60 | — | $1.43 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers